International Symposium on Compound Design Technologies
News Feb 06, 2014
Of particular interest to computational chemists working in the pharmaceutical, biotechnology and drug discovery industries, attendees will hear about technologies that guide them to successful small molecule and biotherapeutic drug discovery and development, intuitive molecular design and 3D-QSAR interpretation as well as knowledge based toxicity prediction.
The keynote presentation will be made by Dr John Overington (EMBL-EBI) with other presentations from Dr. Kimito Funatsu (University of Tokyo), Dr. Yoshio Hamada (Kobe Gakuin University) and Dr. Hiroshi Chuman (University of Tokushima), Dr. Matt Segall (Optibrium), Dr. Tim Cheeseright (Cresset), Dr. Thierry Hanser (Lhasa Limited) and Dr. Mark Swindells (Chemogenomix).
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
New Algorithms Help Extract 3-D Biological Structure from Limited DataNews
CAMERA researchers capitalize on their Multi-Tiered Iterative Phasing approach to determine molecular structure of proteins and viruses from X-ray free electron laser data.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018
EMBL Course: RNA Sequencing Library Preparation - How Low Can You Go?
Mar 19 - Mar 23, 2018
EMBL Course: Analysis and Integration of Transcriptome and Proteome Data
Mar 12 - Mar 16, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018